Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$325.40 USD

325.40
996,860

+3.49 (1.08%)

Updated Nov 8, 2024 03:42 PM ET

After-Market: $324.67 -0.73 (-0.22%) 4:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

The Zacks Analyst Blog Highlights: Amgen, Exxon Mobil, S&P Global, HSBC and LULU

The Zacks Analyst Blog Highlights: Amgen, Exxon Mobil, S&P Global, HSBC and LULU

Stock Market News for Oct 6, 2020

Benchmarks closed higher on Monday as markets cheered news of President Trump???s positive response to Covid-19 treatment, and discharge from hospital.

Why the Earnings Surprise Streak Could Continue for Amgen (AMGN)

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Simple Secrets Anyone Can Use to Reach Early Retirement - October 05, 2020

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Sheraz Mian headshot

Top Stock Reports for Amgen, Exxon Mobil & S&P Global

Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Exxon Mobil (XOM) and S&P Global (SPGI).

Merck Banks on Keytruda, Pipeline & Deals Amid Generic Woes

Keytruda, approved for several types of cancer, alone accounts for more than 25% of Merck's (MRK) pharmaceutical sales Animal health and vaccine products remain core growth drivers.

J&J Simponi Aria Gets FDA Nod for Pediatric Use in Arthritis

FDA approves J&J's (JNJ) Simponi Aria for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA) in patients two years of age and older.

The Extreme Risks of Trading Your Own Retirement Assets - September 30, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

Simple Secrets Anyone Can Use to Reach Early Retirement - September 25, 2020

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

How Trading Your Own Retirement Can Fleece Your Financial Future - September 22, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

Ritujay Ghosh headshot

Trump's Pep Talk Raises Vaccine Hopes: 4 Stocks to Watch

Biotech firms and drugmakers across the globe are pumping in millions of dollars to develop a vaccine to wipe out the deadly coronavirus.

Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies

Eli Lilly (LLY) is developing several potential neutralizing antibodies to treat COVID-19.

The Extreme Risks of Trading Your Own Retirement Assets - September 14, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

J&J Seeks Label Expansion of Darzalex Faspro for Amyloidosis

J&J (JNJ) files sBLA to the FDA for expanding the label of Darzalex Faspro to treat patients with light chain amyloidosis. Currently, there are no approved therapies for the disease.

Easy Investing Secrets to an Early Retirement - September 09, 2020

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN

The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN

Roche Gets FDA Nod for Gavreto for RET Fusion-Positive NSCLC

Roche's (RHHBY) lung cancer arm gets a boost with the FDA approval of Gavreto for NSCLC.

Akebia Falls as Vadadustat Fails to Meet Safety Endpoint

Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.

How Trading Your Own Retirement Can Fleece Your Financial Future - September 04, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

Ritujay Ghosh headshot

Vaccine Hopes Rise Again: 4 Stocks to Watch

The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and Sanofi (SNY).

Sanghamitra Saha headshot

Dow Jones Tops 29,000: Will ETFs & Stocks Rally in September?

The Dow jumped above 29,000 for the first time since February on Sep 2 on low rates and vaccine hopes.

The Zacks Analyst Blog Highlights: PFE, XOM, CRM, AMGN and AAPL

The Zacks Analyst Blog Highlights: PFE, XOM, CRM, AMGN and AAPL

Stock Market News for Sep1, 2020

U.S. stock markets closed mostly lower on Monday as investors booked profit after a week-long rally.

Nilanjan Choudhury headshot

Lessons for Equity Investors From Dow Jones' Big Shake-Up

The Dow Jones is a rare example of an index constructed on the basis of a component's share price.